Ciphergen Announces Pharmaceutical Biomarker Research Collaboration With sanofi-aventis
February 07 2006 - 8:45AM
PR Newswire (US)
Research to Concentrate on Biomarkers for a Pre-Clinical Drug
Efficacy Study in the Field of Oncology FREMONT, Calif., Feb. 7
/PRNewswire-FirstCall/ -- Ciphergen (NASDAQ:CIPH) announced today
that it has extended its existing relationship with sanofi-aventis
by signing a collaborative research agreement. The project will
concentrate on discovery, validation, and identification of
biomarkers for a pre-clinical drug efficacy study in the field of
oncology. Under the terms of the agreement, Ciphergen will analyze
samples at one of its Biomarker Discovery Center(R) laboratories
using its suite of proteomic solutions (Pattern Track(TM) Process,
and ProteinChip(R) System). Financial terms were not disclosed. "We
are extremely pleased to be partnering with sanofi-aventis, an
organization committed to innovation which shares our vision to
accelerate and streamline development of new drugs through the
early identification of relevant drug efficacy biomarkers," stated
Gail S. Page, President and CEO of Ciphergen. "The partnership
allows sanofi-aventis access to our expert scientists and latest
technologies and is an important addition to our translational
proteomics partnerships for drug discovery and development." About
Ciphergen Ciphergen is dedicated to the discovery of protein
biomarkers and panels of biomarkers and their development into
protein molecular diagnostic tests that improve patient care; and
to providing collaborative R&D services through its Biomarker
Discovery Center(R) laboratories for biomarker discovery for new
diagnostic tests as well as pharmacoproteomic services for improved
drug toxicology, efficacy and theranostic assays. Ciphergen
develops, manufactures and markets a family of ProteinChip(R)
Systems and services for clinical, research and process proteomics
applications. ProteinChip Systems enable protein discovery,
validation, identification and assay development to provide
researchers with predictive, multi-marker assay capabilities and a
better understanding of biological function at the protein level.
Additional information about Ciphergen can be found at
http://www.ciphergen.com/. About sanofi-aventis sanofi-aventis is
the world's third-largest pharmaceutical company, ranking number
one in Europe. Backed by a world-class R&D organization,
sanofi-aventis is developing leading positions in seven major
therapeutic areas: cardiovascular disease, thrombosis, oncology,
metabolic diseases, central nervous system, internal medicine, and
vaccines. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in
New York (NYSE:SNY). Safe Harbor Statement Note Regarding
Forward-Looking Statements: For purposes of the Private Securities
Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any
intent or obligation to update these forward-looking statements,
and claims the protection of the Safe Harbor for forward-looking
statements contained in the Act. Examples of such forward-looking
statements include statements regarding efforts to accelerate the
development of new drugs through the identification of drug
efficacy biomarkers. Actual results may differ materially from
those projected in such forward-looking statements due to various
factors, including the possibility that Ciphergen may be
unsuccessful in discovering, validating and identifying useful
biomarkers in this study with sanofi-aventis or in any other study.
Investors should consult Ciphergen's filings with the Securities
and Exchange Commission, including its Form 10-Q dated December 21,
2005, for further information regarding these and other risks of
the Company's business. NOTE: Ciphergen, ProteinChip, and Biomarker
Discovery Center are registered trademarks of Ciphergen Biosystems,
Inc. First Call Analyst: FCMN Contact: scarruthers@ciphergen.com
DATASOURCE: Ciphergen Biosystems, Inc. CONTACT: Sue Carruthers,
Investor Relations of Ciphergen Biosystems, Inc., +1-510-505-2297
Web site: http://www.ciphergen.com/
Copyright
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From May 2024 to Jun 2024
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jun 2023 to Jun 2024